GlobalData
GlobalData

Pharma

Diagnosed prevalent cases of systemic lupus erythematosus across 7MM to reach over 640,000 in 2034, forecasts GlobalData

The diagnosed prevalent cases of systemic lupus erythematosus (SLE) in the seven major markets (7MM*) are set to increase at an annual growth rate (AGR) of 1.17% from over 575,000 in 2024 to 640,000 in 2034, forecasts GlobalData, a leading intelligence and productivity platform. GlobalData’s latest report, “Systemic Lupus Erythematosus and Lupus Nephritis: Epidemiology Forecast […]
Read more

Nucala approval for COPD in China expands precision therapy access with lower eosinophil cutoff, says GlobalData

GSK’s Nucala (mepolizumab) has recently received approval in China as add-on maintenance treatment for adults with inadequately controlled chronic obstructive pulmonary disease (COPD), expanding the shift in treatment access by allowing use at a lower blood eosinophil threshold. The decision broadens eligibility for biologic therapy, strengthens competition in China’s emerging precision COPD market, says GlobalData, […]
Read more

US CMS selects GlobalData’s POLI database as price source for MFN pricing under GLOBE and GUARD price models for Medicare

The US Centers for Medicare and Medicaid Services (CMS) announced that it will use leading intelligence and productivity platform GlobalData’s POLI database to verify prices in the reference countries and set maximum prices for prescription drugs under two Medicare price models based on International Reference Pricing (IRP). The two models, announced in late December 2025, […]
Read more

Meta-analysis strengthens commercial case for broader ERA indication expansion, says GlobalData

A recent research study, conducted by Shi and colleagues and published in the Clinical Journal of the American Society of Nephrology, highlighted compelling evidence that endothelin receptor antagonists (ERAs) offer substantial therapeutic benefits for patients with chronic kidney disease (CKD) while clarifying their safety profile—particularly regarding fluid retention concerns. The meta-analysis strengthens the commercial case […]
Read more

UK–US pharma policies and US manufacturing shape global investment strategies, says GlobalData

The recent UK–US policy developments are reshaping global pharmaceutical investment and launch strategies, as governments on both sides of the Atlantic seek to secure supply, attract capital, and accelerate patient access, says GlobalData, a leading intelligence and productivity platform. In December 2025, the UK announced a landmark pharmaceuticals agreement with the US, granting UK-made medicines […]
Read more

Diagnosed prevalent cases of AMD in Italy projected to increase by 44.09% by 2034, forecasts GlobalData

Diagnosed cases of age-related macular degeneration (AMD) are accelerating across the seven major markets (7MM*), with Italy emerging as the fastest-growing hotspot as prevalence is set to rise more than 44% by 2034. This sharp uptick underscores how aging demographics, lifestyle risks, and chronic comorbidities are converging to intensify long-term pressure on ophthalmology care pathways […]
Read more

Diagnosed incident cases of head and neck cancers in urban China to increase at 3.55% AGR during 2024-2034, forecasts GlobalData

Diagnosed incident cases of head and neck cancers (HNCs) are rising steadily across the eight major markets (8MM*), with urban China set to outpace all others as incidence grows at a 3.55% annual rate through 2034. This trend highlights a pivotal epidemiological transition, where aging populations and evolving risk factors are reshaping disease profiles and […]
Read more

Regenxbio’s clemidsogene lanparvovec approval in Hunter syndrome depends on translating biomarkers to clinical outcomes, says GlobalData

Regenxbio’s clemidsogene lanparvovec has a plausible pathway to FDA approval in Hunter syndrome, although the decision will likely hinge on whether biomarker reductions can be convincingly linked to meaningful clinical outcomes, experts tell the Insights Investigative News team at GlobalData, a leading intelligence and productivity platform. Clemidsogene lanparvovec is a CNS-directed gene therapy designed to […]
Read more

Biopharma enters 2026 with renewed and cautious optimism, says GlobalData

Against the backdrop of a turbulent year marked by both breakthrough and setbacks, the biopharmaceutical industry is entering 2026 with renewed confidence. Industry optimism and investment sentiment have strengthened, although cautiously, according to a new report by GlobalData, a leading intelligence and productivity platform. In 2025, the biopharmaceutical industry began the year with strong scientific […]
Read more

PCSK9 approval marks shift to long-acting LDL-C control in high-risk cardiovascular patients, says GlobalData

Once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) therapy has moved into a new phase with FDA approval of LIB Therapeutics’ Lerochol for adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). The approval highlights a clear industry shift toward long-acting, adherence-focused lipid-lowering options as payers, clinicians, and innovators prioritize sustained LDL-C control in high-risk cardiovascular […]
Read more

US affordability reforms and multibillion-dollar manufacturing expansions to reshape global pharmaceutical strategy, says GlobalData

A wave of transformative US drug-pricing agreements and record manufacturing investments from leading biopharmaceutical companies is poised to reshape the global landscape for pharmaceutical access, production, and industrial policy, according to GlobalData, a leading data and analytics company. In November 2025, the Trump administration advanced its Most-Favored-Nation (MFN) pricing program through landmark agreements with Eli […]
Read more

FDA approval of Blujepa and Nuzolvence signal new era in treatment of gonorrhea, says GlobalData

Following the news that the FDA has approved GSK’s Blujepa (gepotidacin) and Innoviva’s Nuzolvence (zoliflodacin) for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents:  Fiona Chisholm, Associate Director of Infectious Diseases at GlobalData, a leading data and analytics company, offers her view: “Blujepa and Nuzolvence are the first drugs from new antibiotic classes […]
Read more

Diagnosed prevalent cases of diabetic macular edema (DME) across 7MM to reach 3.46 million in 2034, forecasts GlobalData

The diagnosed prevalent cases of diabetic macular edema (DME) in the diabetes population across the seven major markets (7MM*) are expected to increase at an annual growth rate (AGR) of 1.99% from 2.89 million in 2024 to 3.46 million in 2034, forecasts GlobalData, a leading data and analytics company. GlobalData’s report, “Diabetic Macular Edema (DME) […]
Read more

Priligy to get first mover advantage as CAR-T therapy for pediatric r/r B-cell acute lymphoblastic leukemia in China, says GlobalData

China is making significant strides in CAR-T innovation. Recently, Chongqing Precision Biotech Co., Ltd. received approval for Priligy (priscabtagene autoleucel) to treat pediatric and adolescent patients aged 3 to 21 years with CD19-positive relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). With this approval, Priligy is expected to gain a first-mover advantage as a CAR-T therapy […]
Read more

Cell and gene therapy investments shift as budgets tighten and big pharma recalibrates towards strategic acquisitions, says GlobalData

The cell and gene therapy (CGT) sector is undergoing a transition as companies navigate a more selective and strategy-driven funding landscape, according to an analysis by the Pharma Strategic Intelligence team at GlobalData, a leading data and analytics company. While venture capital (VC) investment in CGTs has declined in recent years after a peak during […]
Read more